国产人妖在线视频I午夜av一区二区三区I国产色一区二区I一级片视频在线观看I一级毛片儿I亚色图I丁香花一区二区I超碰97在线免费I久久精品中文字幕I日韩在线视频观看免费I无码中文字幕色专区I欧美专区亚洲专区I国产tv在线观看I2024最新黄色网址I日本老妇高潮乱hdI成人免费入口I日韩精品视频在线看I国产传媒在线播放I一本岛视频在线观看I自拍日韩亚洲一区在线I国产成人亚洲综合a∨婷婷I国产精品2019I色亚洲天堂Iav黄色免费I欧美大尺度视频

myocardial infarction is myocardial cell death caused by myocardial ischemia and hypoxia, which is one of the main causes of death of cardiovascular diseases.

Current treatments are mainly drug therapy, thrombolysis, stent placement and bypass grafting, but these methods cannot fundamentally repair the damaged heart and restore the heart function. Engineered stem cells refer to the stem cells cultured, expanded, differentiated or modified in vitro, and have certain biological characteristics and functions. The principle of engineered stem cells for the diagnosis and treatment of myocardial infarction is to transplant to the damaged heart, promote myocyte regeneration, blood vessel regeneration, suppression of inflammation, and immune regulation, so as to improve cardiac remodeling and function. The methods used by engineering stem cells for the diagnosis and treatment of myocardial infarction mainly include direct injection, coronary perfusion and stent implantation, among which direct injection is the most simple, but there are also problems of low cell survival rate and uneven distribution. The effect of engineered stem cells for the diagnosis and treatment of myocardial infarction is still controversial. Different animal models and clinical trials have shown inconsistent results, which may be related to the cell type, source, dose, route, timing and other factors. The challenges of engineered stem cells for the diagnosis and treatment of myocardial infarction mainly include improving the quality and quantity of cells, optimizing the conditions and methods of transplantation, solving the risks of xenograft rejection and tumor formation, and monitoring the effect and safety after transplantation.
Combined with biomimetic strategy to modify exosomes, realize targeted therapy of cardiac repair, using engineered exosomes to promote myocardial vascularization and vascularization and functional recovery after myocardial infarction.